Polysialic Acid Glycomimetic Promotes Functional Recovery and Plasticity After Spinal Cord Injury in Mice

Molecular Therapy, 2010 · DOI: 10.1038/mt.2009.235 · Published: January 1, 2010

Spinal Cord Injury Regenerative Medicine Neurology

Simple Explanation

This study explores ways to improve recovery after spinal cord injury by using molecules that mimic the effects of certain carbohydrates known to help nerve cells grow. These carbohydrates, called polysialic acid (PSA) and human natural killer cell-1 (HNK-1), are important for nerve regeneration and connection. The researchers tested peptides that mimic PSA and HNK-1 in mice with spinal cord injuries. They found that a PSA mimetic, especially when combined with an HNK-1 mimetic, improved the mice's ability to move after the injury. The PSA mimetic appeared to work by helping to rebuild connections between nerve cells in the injured spinal cord. However, this treatment was only effective when started soon after the injury, suggesting a limited window for this kind of therapy.

Study Duration

6 weeks

Participants

Young adult C57BL/6J mice (n = 7–8 per group)

Evidence Level

Level II: Animal study

Key Findings

1
Treatment with PSA mimetic, alone or in combination with HNK-1 mimetic, improved functional outcome of compression spinal cord injury compared with the control treatment.
2
The PSA mimetic treatment was effective only when initiated during the acute phase of spinal cord injury, and not when initiated 3 weeks after injury.
3
PSA mimetic treatment led to enhanced monoaminergic innervation of the spinal cord, increased cholinergic terminals on lumbar motoneurons, and higher numbers of glutamatergic terminals in lamina VII of the spinal gray matter.

Research Summary

This study investigated the potential of PSA and HNK-1 mimetics to promote regeneration and functional recovery after spinal cord injury in mice. The mimetics were delivered via subdural infusions using osmotic pumps. The results showed that immediate post-traumatic administration of the PSA mimetic, alone or in combination with the HNK-1 mimetic, improved locomotor function. This was associated with increased numbers of cholinergic and glutamatergic terminals, as well as enhanced monoaminergic innervation in the lumbar spinal cord. The therapeutic time window for the PSA mimetic was limited to the acute phase of spinal cord injury, as treatment initiated 3 weeks post-injury was ineffective. The study suggests that PSA mimetic peptides can be efficient therapeutic tools for improving functional recovery by augmenting plasticity when applied early after spinal cord injury.

Practical Implications

Therapeutic Potential

PSA glycomimetics may offer a clinically feasible therapeutic approach for spinal cord injury, as they can be readily synthesized and administered subdurally.

Timing is Critical

The study highlights the importance of early intervention, suggesting that PSA mimetic treatment is most effective when administered during the acute phase of spinal cord injury.

Plasticity Enhancement

The findings support the notion that promoting plasticity in the spinal cord is crucial for improving functional outcomes after injury, and that PSA mimetics can play a role in this process.

Study Limitations

1
The study was conducted in mice, and the results may not be directly applicable to humans.
2
The therapeutic time window of the PSA mimetic appears to be limited to the acute phase of spinal cord injury.
3
The study did not fully elucidate the molecular mechanisms underlying the beneficial effects of the PSA mimetic.

Your Feedback

Was this summary helpful?

Back to Spinal Cord Injury